Refine Results
  1. "Lymphoma Disease Management Team"
Formats
  1. Journal Article (2041)
  2. Meeting Abstract (1578)
  3. Book Section (127)
  4. Conference Paper (8)
  5. Book Whole (3)
Groups
  1. Lymphoma Disease Management Team (3757)
  2. Center for Hematologic Malignancies (1689)
  3. Hematologic Oncology, Division of (1641)
  4. Lymphoma Service (1447)
  5. Lymphoma (1252)
  6. Myeloma Disease Management Team (1074)

More Groups

People
  1. Andrew Zelenetz (538)
  2. Kenneth Offit (476)
  3. Joachim Yahalom (377)
  4. Craig Moskowitz (366)
  5. Steven Horwitz (338)
  6. Maria Arcila (321)

More People

Years
  1. 2019 (4)
  2. 2018 (211)
  3. 2017 (303)
  4. 2016 (293)
  5. 2015 (332)
  6. 2014 (307)

More Years

Publications
  1. Blood (621)
  2. Journal of Clinical Oncology (367)
  3. International Journal of Radiation Oncology, Biology, Physics (138)
  4. Modern Pathology (138)
  5. Laboratory Investigation (121)
  6. Cancer Research (85)

More Publications

Publishers
  1. American Society of Hematology (632)
  2. Nature Publishing Group (401)
  3. American Society of Clinical Oncology (377)
  4. Elsevier Inc. (349)
  5. American Association for Cancer Research (203)
  6. Springer (179)

More Publishers

Results (3757)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Interinstitutional variation in predictive value of the ThyroSeq v2 genomic classifier for cytologically indeterminate thyroid nodules
    Journal Article

    Marcadis, A. R.; Valderrabano, P.; Ho, A. S.; Tepe, J.; Swartzwelder, C. E.; Byrd, S.; Sacks, W. L.; Untch, B. R.; Shaha, A. R.; Xu, B.; more...
    Surgery (2019)

    Fulltext@MSK | Save
  • Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutations
    Journal Article

    Manley, B. J.; Reznik, E.; Ghanaat, M.; Kashan, M.; Becerra, M. F.; Casuscelli, J.; Tennenbaum, D.; Redzematovic, A.; Carlo, M. I.; Sato, Y.; more...
    Urologic Oncology: Seminars and Original Investigations (2019)

    Fulltext@MSK | Save
  • Discovery of common and rare genetic risk variants for colorectal cancer
    Journal Article

    Huyghe, J. R.; Bien, S. A.; Harrison, T. A.; Kang, H. M.; Chen, S.; Schmit, S. L.; Conti, D. V.; Qu, C.; Jeon, J.; Edlund, C. K.; more...
    Nature Genetics (2019)

    Fulltext@MSK | Save
  • Stereotactic breast biopsy efficiency: Does a pre-biopsy grid image help?
    Journal Article

    Mango, V. L.; D'Alessio, D.; Morris, E. A.; Ha, R.; Bernard-Davila, B.; Jochelson, M.
    Clinical Imaging (2019)

    Fulltext@MSK | Save
  • Detecting HER2 alterations by next generation sequencing (NGS) in patients with advanced NSCLC from the United States and China
    Meeting Abstract

    Xu, C.; Zhang, Y.; Liu, D.; Shen, R.; Razavi, P.; Liu, S.; Sun, H.; Offin, M.; Drilon, A.; Rudin, C.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Pan-cancer microsatellite instability to predict for presence of Lynch syndrome
    Meeting Abstract

    Latham Schwark, A.; Srinivasan, P.; Kemel, Y.; Shia, J.; Bandlamudi, C.; Mandelker, D.; Dubard-Gault, M.; Tran, C.; Middha, S.; Hechtman, J. F.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER
    Meeting Abstract

    Baselga, J.; Dent, S. F.; Cortés, J.; Im, Y. H.; Diéras, V.; Harbeck, N.; Krop, I. E.; Verma, S.; Wilson, T. R.; Jin, H.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Initial results of a dose escalation study of a selective and structurally differentiated PI3K delta inhibitor, ME-401, in relapsed/refractory (R/R) follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
    Meeting Abstract

    Soumerai, J. D.; Pagel, J. M.; Jagadeesh, D.; Salman, H. S.; Kenkre, V. P.; Asch, A. S.; Stathis, A.; Reddy, N. M.; Iasonos, A.; Ghalie, R.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL
    Meeting Abstract

    Sehn, L. H.; Kamdar, M.; Herrera, A. F.; McMillan, A.; Flowers, C.; Kim, W. S.; Kim, T. M.; Özcan, M.; Demeter, J.; Hertzberg, M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/refractory B- and T-cell non-Hodgkin lymphoma (NHL)
    Meeting Abstract

    Hamlin, P. A.; Cheson, B. D.; Farber, C. M.; Feldman, T.; Fenske, T. S.; Hess, B. T.; Khatcheressian, J. L.; Miller, C. B.; Munoz, J.; Patel, M. R.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save